BR112021003830A2 - métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida - Google Patents

métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida Download PDF

Info

Publication number
BR112021003830A2
BR112021003830A2 BR112021003830-2A BR112021003830A BR112021003830A2 BR 112021003830 A2 BR112021003830 A2 BR 112021003830A2 BR 112021003830 A BR112021003830 A BR 112021003830A BR 112021003830 A2 BR112021003830 A2 BR 112021003830A2
Authority
BR
Brazil
Prior art keywords
cells
cell
notch
car
days
Prior art date
Application number
BR112021003830-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Stanley R. Riddell
Irwin D. Bernstein
Margot J. Pont
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of BR112021003830A2 publication Critical patent/BR112021003830A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
BR112021003830-2A 2018-08-28 2019-08-28 métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida BR112021003830A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723936P 2018-08-28 2018-08-28
US62/723,936 2018-08-28
PCT/US2019/048574 WO2020047099A1 (en) 2018-08-28 2019-08-28 Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Publications (1)

Publication Number Publication Date
BR112021003830A2 true BR112021003830A2 (pt) 2021-07-20

Family

ID=67982131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021003830-2A BR112021003830A2 (pt) 2018-08-28 2019-08-28 métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida

Country Status (9)

Country Link
US (1) US20210292711A1 (https=)
EP (1) EP3844266A1 (https=)
JP (1) JP2021534785A (https=)
CN (1) CN112930393A (https=)
AU (1) AU2019329984A1 (https=)
BR (1) BR112021003830A2 (https=)
CA (1) CA3110089A1 (https=)
SG (1) SG11202101455TA (https=)
WO (1) WO2020047099A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241335A1 (en) * 2019-07-11 2022-08-04 H. Lee Moffitt Cancer Center And Research Inst5Itute, Inc. Engineering notch ligands to enhance the anti-tumor activity of adoptively transferred t cells
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022165367A1 (en) * 2021-01-29 2022-08-04 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
CN113832102B (zh) * 2021-09-27 2024-03-12 苏州东岭生物技术有限公司 Cd3/cd28/dll4磁珠及其制备方法和应用
CN116716349B (zh) * 2023-08-01 2023-10-31 江苏集萃药康生物科技股份有限公司 一种dll4人源化小鼠模型的构建方法及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA136551A (en) 1911-08-03 1911-10-31 Hedwig Heeron Rolling mill
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
CN1524583A (zh) * 1996-11-07 2004-09-01 能够表达Notch-配体的基因在制备用于免疫治疗的药物中的应用
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US20030119771A1 (en) 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
JP2003093048A (ja) * 2001-09-26 2003-04-02 Asahi Kasei Corp 新規細胞製剤製造用培養媒体
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
AU2003226537A1 (en) * 2002-04-05 2003-10-27 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1549347A1 (en) * 2002-10-09 2005-07-06 Lorantis Limited Modulation of immune function
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
CA2589279A1 (en) * 2004-11-24 2006-06-01 Val-Chum, S.E.C. Methods to identify, prepare, and use naive t cell recent thymic emigrants
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
PE20080891A1 (es) 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
WO2008092445A2 (de) * 2007-01-30 2008-08-07 Deutsches Rheuma-Forschungszentrum Berlin Verfahren zur modulation der immunantwort durch aktivierung oder inaktivierung des notch und/oder stat4 signalweges
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2010141249A2 (en) 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10696946B2 (en) * 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
US9683039B2 (en) 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
CA2948871A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
CN106459919B (zh) 2014-06-04 2021-03-23 弗莱德哈钦森癌症研究中心 使用notch 1和/或notch 2激动剂扩增和植入干细胞
HK1243631A1 (zh) * 2014-10-27 2018-07-20 Fred Hutchinson Cancer Research Center 用於提高过继细胞免疫疗法效力的组合物和方法
US10947502B2 (en) * 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
AU2016341529B2 (en) * 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
SG11201803419PA (en) * 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
US11261250B2 (en) 2016-07-22 2022-03-01 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions

Also Published As

Publication number Publication date
SG11202101455TA (en) 2021-03-30
JP2021534785A (ja) 2021-12-16
US20210292711A1 (en) 2021-09-23
AU2019329984A1 (en) 2021-03-11
WO2020047099A1 (en) 2020-03-05
CA3110089A1 (en) 2020-03-05
CN112930393A (zh) 2021-06-08
EP3844266A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US11458191B2 (en) Binding proteins specific for RAS neoantigens and uses thereof
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
BR112021003830A2 (pt) métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
CN110997902B (zh) Suv39h1缺陷的免疫细胞
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US20240165232A1 (en) Chimeric receptor proteins and uses thereof
TW202402798A (zh) 對新抗原具特異性之結合蛋白與工程化細胞及其用途
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP2020533962A (ja) Ｂｒａｆ特異的ｔｃｒおよびその使用
US20220267403A1 (en) Binding proteins specific for 5t4 and uses thereof
US20220009992A1 (en) T cell receptors specific for mesothelin and their use in immunotherapy
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
WO2022165367A1 (en) Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
WO2024163371A1 (en) Binding proteins specific for mutant p53 and uses thereof
JP2024520492A (ja) Ｎｒ４ａ３欠損免疫細胞及びその使用
HK40073285A (en) T-cell immunotherapy specific for wt-1
HK40040021A (en) Enhanced chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.